Indian healthcare sector experienced 85% surge in deal value in H1FY23

With India assuming the G20 presidency and the Asia-Pacific group due to host COP28, there is a significant opportunity for the country to highlight its constructive climate policies and showcase its capabilities to become a global clean manufacturing hub. However, with the ongoing market volatility and high global interest rates the deal situation remains subdued. Inflation continues to be sticky in most countries primarily due to unchanged external macro-economic circumstances – the Ukraine conflict, Sino-American rivalry and the post pandemic slowdown in China among others.

Among the sectors, the automotive sector recorded 16 deals, financial services 52 deals, retail and consumer sector 72 deals and technology sector 99 deals. In the tech sector, while the deal value remained subdued as compared to the previous year, there is a marginal improvement in the quarterly deal activity in Q2 2023, as compared to Q1 2023. The pharma and healthcare sector reported an increase in deal value, while the volume remained low. The deal activity shifted from healthtech organisations in the previous quarters, to hospitals.

H1 2023 highlights

• In the automotive sector, Samvardhana Motherson International Ltd.’s acquisition of SAS Autosystemtechnik GmbH & Co worth USD 578 million accounted for 51% of overall values in H1 2023 and marked the largest outbound deal in this sector since 2021.
• In the financial services sector, H1 2023 witnessed a 46% decline in volumes and a strong 92% decline in values recording only 92 deals valued at USD 3.7 billion. This is due to one of the biggest deals in Indian history ─ merger of HDFC and HDFC Bank worth USD 40 billion.
• In the pharma, healthcare and biotech sector, H1 2023 reported an 85% increase in deal values compared to H1 2022, despite marginally low deal volumes.
• In the retail and consumer goods sector H1 2023 saw only 150 deals valued at USD 2.8 billion, nearly a 50% drop in volumes and 61% decline in deal values over H1 2022.
• The deal activity in the technology sector experienced a substantial decline in H1 2023, with volumes falling by 46% and values dropping by 94%. Although there were notable high-value transactions, H1 2022 outperformed H1 2023 in terms of deal activity in the sector.

Key highlights – Pharma, healthcare and biotech

• 17% decline in deal volumes compared to Q2 2022; a remarkable 146% increase in deal values, from USD 1.3 billion in Q2 2022 to USD 3.1 billion in the current quarter due to a few significant transactions
• In PE deals, Temasek Holdings acquired stakes of Manipal Health Enterprises from TPG Capital Management for USD 2 billion, marking the sector’s largest fundraise in 13 years.
• In another notable transaction, Blackstone Group bought stakes in Quality CARE India Limited ─ Care Hospitals for USD 560 million.
• M&A recorded a 60% increase in deal volumes, recording 16 deals. Deal values surged by 97% to reach USD 487 million, resulting in an average ticket size of USD 30 million, compared to USD 25 million in Q2 2022.

For report click: Pharma, healthcare and biotech dealtracker. Grant Thornton